PEP
36
3
PG
43
2
FLR
52
2
UNP
40
2
MRK
27
2
LH
38
5
GT
47
4
ORCL
55
6
TGT
47
3
PVH
62
4
HBAN
47
3
MMM
37
2
DTE
54
5
GPC
35
6
SLB
45
4
PX
58
5
NTRS
44
5
QRVO
20
2
RHI
50
2
AVGO
79
3
PEP
36
3
PG
43
2
FLR
52
2
UNP
40
2
MRK
27
2
LH
38
5
GT
47
4
ORCL
55
6
TGT
47
3
PVH
62
4
HBAN
47
3
MMM
37
2
DTE
54
5
GPC
35
6
SLB
45
4
PX
58
5
NTRS
44
5
QRVO
20
2
RHI
50
2
AVGO
79
3
Financhill
Back

Marinus Pharmaceuticals 10K Form

Sell
41

MRNS
Marinus Pharmaceuticals

Last Price:
$0.26
Seasonality Move:
10.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08 10Q MRNS/Marinus Pharmaceuticals Quarterly
2023-11-07 10Q MRNS/Marinus Pharmaceuticals Quarterly
2023-08-10 10Q MRNS/Marinus Pharmaceuticals Quarterly
2023-05-11 10Q MRNS/Marinus Pharmaceuticals Quarterly
2022-11-07 10Q MRNS/Marinus Pharmaceuticals Quarterly
2022-08-11 10Q MRNS/Marinus Pharmaceuticals Quarterly

Receive MRNS News And Ratings

See the #1 stock for the next 7 days that we like better than MRNS

MRNS Financial Statistics

Sales & Book Value

Annual Sales: $31M
Cash Flow: $-20.6M
Price / Cash Flow: 0
Annual Sales: $-1.21
Price / Book: 0

Profitability

EPS (TTM): -2.47000
Net Income (TTM): $-140.5M
Gross Margin: $29.1M
Return on Equity: -1150.43%
Return on Assets: -106.47%

Marinus Pharmaceuticals Earnings Forecast

Key Marinus Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 8 years for MRNS is 93.76%.
  • The Selling, General & Administrative Expenses for MRNS have been equal to 197.33% of Gross Profit Margin.
  • The Research & Development expenses have been 320.72% of Revenue.
  • The Interest Expense is -11.95% of Operating Income.
  • The Net Earning history of MRNS is -456.31% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Marinus Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: MRNS
CUSIP: 56854Q
Website: marinuspharma.com

Debt

Debt-to-Equity Ratio: -0.83
Current Ratio: 1.66
Quick Ratio: 1.33

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRNS Technical Analysis vs Fundamental Analysis

Sell
41
Marinus Pharmaceuticals (MRNS) is a Sell

Is Marinus Pharmaceuticals a Buy or a Sell?